Since the differences in the efficacy or safety between anti-PD-1 and anti-PD-L1 immunotherapies have not been undefined even for human, it might be difficult to perform clinical studies to prove the superiority of ours and Maekawa’s group’s one20 with a sufficient number of tumor cases in veterinary field. The gene discussed is PDCD1; the disease is neoplasm.